text:
Evans Hydraulic Blue Bass Drum Head, 22 Inch
- Description
- Features
- Delivery & Returns
- Warranty & 30-Day Money Back Guarantee
The Evans Hydraulic Blue Drum Head features a thin layer of oil between the two plies to suppress overtones and improve sound quality. The Hydraulic head provides a deep sound with a short sustain, ideal for a wide range of drumming styles. Hydraulic Drum heads offer the best sound possible with minimal tuning.
- 2 ply Drum Head
- Thin layer of oil to suppress overtones
- Blue finish provides a great aesthetic
- Suitable for a wide range of styles
At Drum Central we want you to be able to shop with confidence and are happy to offer a 2 year warranty and 30 day money back guarantee on all of our new products. (All products sold are considered new unless clearly stated. This includes ex display models.)
If within 30 days of receiving your purchase you decide it is not right for you providing it is returned in "as new" condition within its unopened original packing we will refund or exchange your item as desired. In cases where packaging has been opened we may be unable to offer a refund but in some cases will offer a refund that reflects the reduced resale value of the item.
We do our best to make sure every aspect of your Drum Central order goes smoothly but in the event that an item arrives either damaged or incorrect then notify us within 14 days and we will arrange a free collection so as to get the item swapped or replaced.
If your purchase develops a fault within the 2 year warranty period you can return it to us and we will repair or replace it. A fault is defined as a defect that you would not normally expect to occur through normal wear and tear and that has not been caused by improper use.
Estimated Delivery Date 17/12/2023SKU: BD22HB
What Our Customers Think
The DC guys really know their stuff. Best drum store in Scotland. Will be back!
Donavan HepburnDrummer - Take That, ELO
Thanks again drum central! Always great service and quick delivery.
Mark RichardsonDrummer - Skunk Anansie


text:
Why use an agent with F.C. Tucker Emge and F.C. Tucker Collier REALTORS?
Posted by Geri Terry on Thursday, December 11, 2014 at 6:55:23 AM By Geri Terry / December 11, 2014 Comment
Why use an agent with F.C. Tucker Emge and F.C. Tucker Collier REALTORS?
At F.C. Tucker Emge and F.C. Tucker Collier REALTORS, I can be your single point of contact for all of your real estate needs. When you need brokerage, commercial, auction, relocation, title or home warranty services, I can make your transaction a success.
Being associated with the number one real estate company in Indiana gives me the resources that allow me to devote more time to you.
- Size – Size – Over 47 offices throughout Indiana and 8 offices in Southwestern Indiana and Western Kentucky.
- FCTuckerEmge.com – The area's most reliable and most visited real estate website.
- Worldwide Referral Network – Leading Real Estate Companies of the World, the world's oldest and largest real estate referral network.
- Online Exposure – FCTuckerEmge.com, the premier site for real estate information.
- MyTucker – It's fast, it's free and it's another Tucker exclusive.

subset: commoncrawl


text:
|0.35 kg
|Lace Size
08 inch, 10 inch, 12 inch, 14 inch, 16 inch, 18 inch, 20 inch, 22 inch, 24 inch, 26 inch, 28 inch
Deep Curly White Blonde Lace Closure Wig
Contact with us if you're a wholesale hair vendors
seeking a supplier at factory prices.
From 82.0$/ Piece
Having a beautiful hairstyle that can make everyone look at you with affection is a cool idea, right? Now with our curly blonde lace wigs, you can have a gorgeous and attractive look in a blink of an eye.
- 100% Remy human hair
- 10,000 products and more
- Variations in lengths, colors, and textures
- Readily dyed and bleached
- Unbeatable prices
LUXSHINEHAIR works with a variety of shipping agents. The most popular courier service like DHL, FedEx, Cedex, UPS, EMS is available based on your region. You will receive a confirmation from our sales agent once your order is ready to be shipped.
Can I color these hair extensions?
Answer: Yes you can. We only recommend dying the virgin #1B color, they are completely natural and will take color easily from to 2 to 3 shades. If you need to go lighter then bleaching may be involved, in which case we would recommend you consult a professional. We do not recommend coloring hair that's already been colored. When doing any color service to the hair, perform a test strand first to see how the color processes with your formula being used. Once you confirm the results and processing time are correct than you can carry on with the full application of color desired. Keep in mind that the lighter you go it may slightly loosen the hair's natural curl pattern. This is something you can check for after completing your strand test as well.
How long will this hair last?
Answer: With proper care and maintenance, this overall product will last you at least 1 to 2 years with proper care. We have customers that have been using the same hair extensions upwards of 4 to 5 years. We recommend only using the highest quality hair extension products for maintenance.
What kind of hair are used in these?
Answer: We use 100% authentic Remy hair in all of our hair extension products. The virgin #1B color is natural, other colors are also available for purchase. The cuticle remains intact and aligned which allows the hair to be styled naturally with heat tools so it blends seamlessly with your own hair.
Are other colors available?
Answer: This product is only available in the virgin #1B color, which is a beautiful combination of off-black and dark brown.


text:
Aluminium Sports Bottle(1000ML) - Corporate Gifts, Premium Gifts, Souvenirs
- $0
Availability: In Stock
Product Code: S985
|Souvenir Name
|1000ML Aluminium Sports Bottle
|Product Size
|46 x 31.5 x 33 CM
|Sample Lead Time
|10 Days
|Production Lead Time
|30 Days
|Product Net Weight
|Carton Gross Weight
If you are interested in this product, please fill the following contact form and write down your request clearly. We will reply you as soon as possible.
Selecting The Correct Corporate Gifts
From the perspective of business-to-business, corporate gifts, when personalized, can include office mugs, thermal mugs, stationery, promotional pen, and USB Flash Drive etc. The core function of most Corporate Gifts is to develop positive long-term client relationships, showing appreciation by rewarding loyal customers and referral sales lead for their business. Remember that while promoting your business products, or services, Corporate Gifts, are also great gifts of sincerity. It is amazing to enhance the reputation and image of your company by sending personalized gifts, as corporate gifts. Among givers of Corporate Gifts, there are certainly many reasons to give to your customers as well as your business partners. Most Sympathy Gifts from your company can express respect when the Business Gifts, are personalized. How about a Congratulations Gift for being awarded a long term cooperation project? Or tailor-made metal pen with bright package to the staff members of a competitive business simply to acknowledge their years of hard work. Stick with appropriate gifts you know and you won't go wrong. Whatever you choose to send, always remember that any gift you send is the representative of your company.
The right Corporate Gifts can improve your corporate identity and business image.
Staff members are expecting more now, by expressing a gesture of togetherness, a thank you gift is given to reward and motivate employees. Business Gifts are essential elements of the corporate identity of a company. If selected properly, corporate gifts can convey acceptance of behavior and good will. Corporate gifts can enhance a business relationship and improve customer loyalty. In any occasion, i-CorporateGifts can help make a lasting impression by creating personalized gifts. A daily stationary in office with personalized to your exacting criteria, can go a long way toward generating a long-lasting bond.


text:
Contact Info
24948 Wolf Bay Ter
Orange Beach, Alabama 36561
Orange Beach, Alabama 36561
- Phone 1:
- 251-968-6994
Alabama's capital and second largest city is packed with Civil War and Civil Rights sights all an easy drive away from historic Tuskeegee University.
Use our easy Lodging Search to find exactly the type of accommodation you are looking for at the right price.Search Now
Switch to Mobile Browser Mode
We offer a compact version of Go-Alabama for mobile users, allowing you to access just the information you need on the road. Of course, you can still use the full version of Go-Alabama on your mobile device just as you can on your desktop.


text:
Customize your JAMA Network experience by selecting one or more topics from the list below.
To investigate the efficacy and safety of 4 antipseudomonal treatments in children with cystic fibrosis with recently acquired Pseudomonas aeruginosa infection.
Randomized controlled trial.
Multicenter trial in the United States.
Three hundred four children with cystic fibrosis aged 1 to 12 years within 6 months of P aeruginosa detection.
Participants were randomized to 1 of 4 antibiotic regimens for 18 months (six 12-week quarters) between December 2004 and June 2009. Participants randomized to cycled therapy received tobramycin inhalation solution (300 mg twice a day) for 28 days, with oral ciprofloxacin (15-20 mg/kg twice a day) or oral placebo for 14 days every quarter, while participants randomized to culture-based therapy received the same treatments only during quarters with positive P aeruginosa cultures.
Main Outcome Measures
The primary end points were time to pulmonary exacerbation requiring intravenous antibiotics and proportion of P aeruginosa –positive cultures.
The intention-to-treat analysis included 304 participants. There was no interaction between treatments. There were no statistically significant differences in exacerbation rates between cycled and culture-based groups (hazard ratio, 0.95; 95% confidence interval [CI], 0.54-1.66) or ciprofloxacin and placebo (hazard ratio, 1.45; 95% CI, 0.82-2.54). The odds ratios of P aeruginosa– positive culture comparing the cycled vs culture-based group were 0.78 (95% CI, 0.49-1.23) and 1.10 (95% CI, 0.71-1.71) comparing ciprofloxacin vs placebo. Adverse events were similar across groups.
No difference in the rate of exacerbation or prevalence of P aeruginosa positivity was detected between cycled and culture-based therapies. Adding ciprofloxacin produced no benefits.
Trial Registration
ClinicalTrials.gov Identifier: NCT00097773.
Pseudomonas aeruginosa, the predominant pathogen associated with chronic infection in cystic fibrosis (CF),1 results in more rapid decline in lung function, increased hospitalization, and decreased survival2,3 starting in the first decade of life.1,4-16 Several randomized trials16-19 and a cohort study20 demonstrated that inhaled antibiotics (colistin or tobramycin) with or without oral fluoroquinolones may result in prolonged eradication of early (nonchronic) P aeruginosa acquisition.16,21,22 Although spontaneous clearance may occur in some patients,18,19 data suggest that antibiotics might be superior to no treatment.23 Based on these data, aggressive antibiotic treatment at initial P aeruginosa airway detection has been recommended using a range of antibiotic strategies and treatment duration.24-26
It remains unclear whether clearance of P aeruginosa from airway cultures has any impact on other health indicators such as exacerbation of respiratory symptoms (pulmonary exacerbation [PE]27), lung function, hospitalization, and growth.28 While there is potential to benefit from early intervention, concerns remain regarding the risks of long-term antibiotic exposure and selection of resistant bacterial pathogens.29
Quiz Ref IDWe compared the clinical and microbiological effectiveness as well as the safety of 4 antibiotic treatment strategies for newly identified P aeruginosa infection isolated from respiratory cultures in children with CF.30 We hypothesized that more frequent administration and double antibiotic therapy would result in reduced rates of PE and frequency of P aeruginosa– positive respiratory cultures over an 18-month study period. We report herein the results of the largest randomized controlled trial of antibiotic therapies to treat P aeruginosa detection ever conducted in young children with CF.
We conducted a multicenter, randomized trial of young children with CF at the time of new isolation of P aeruginosa in respiratory tract cultures. Eligible participants were recruited at 55 Cystic Fibrosis Foundation–accredited clinical centers throughout the United States (see "EPIC Participating Centers and Investigators" box). The duration of study participation was 18 months. All centers obtained institutional review board approval, and all participants' parent or legal guardian provided informed consent. Details of the study design are presented elsewhere.30
Quiz Ref IDMale and female subjects 1 year or older and 12 years or younger with a diagnosis of CF31 with a documented respiratory tract culture positive for P aeruginosa within the 6 months prior to randomization were eligible. New isolation of P aeruginosa was defined as the first lifetime documented respiratory positive culture or as a positive culture after at least a 2-year absence of P aeruginosa growth. Among participants aged 12 to 15 months, at least 1 P aeruginosa– positive respiratory culture since birth was required. No more than 1 course of inhaled or intravenous antipseudomonal therapy was allowed prior to baseline. Additional detailed eligibility criteria have been previously reported.30
Quiz Ref IDParticipants were equally randomized to 1 of 4 antipseudomonal treatment algorithms
(eTable 1): (1) scheduled antimicrobial therapy consisting of tobramycin inhalation solution (TIS) combined with oral ciprofloxacin every 3 months (cycled TIS and oral ciprofloxacin); (2) scheduled TIS combined with oral placebo every 3 months (cycled TIS and oral placebo); (3) TIS combined with oral ciprofloxacin only when quarterly respiratory cultures were found positive for P aeruginosa (culture-based TIS and oral ciprofloxacin); and (4) TIS combined with oral placebo only when quarterly respiratory cultures were found positive for P aeruginosa (culture-based TIS and oral placebo). The antimicrobial therapy administered during treatment cycles was open-label TIS (TOBI), 300 mg twice a day for 28 days, and either oral ciprofloxacin (Cipro), 15 to 20 mg/kg/dose up to 750 mg/dose twice a day, or oral placebo for 14 days. A 14-day ciprofloxacin course was chosen to minimize the emergence of P aeruginosa resistance.32,33 At the beginning of the study, all participants received an initial treatment cycle according to their assigned group and a second consecutive 28-day course of TIS monotherapy if respiratory cultures sampled during the third week of the first antipseudomonal cycle remained P aeruginosa positive
(eTable 1).
Participants had study visits at the time of randomization, 3 weeks later, and then quarterly for a total of 18 months.30 Oropharyngeal swabs, or sputum cultures, if available, were obtained at each study visit. Semiquantitative bacterial cultures were processed at a central microbiology laboratory.34 All P aeruginosa isolates were assessed for mucoid phenotype, and antibiotic susceptibility testing of all CF pathogens was performed.30 Cultures sampled for clinical indications and processed at local laboratories were not included in the evaluation of the microbiological study end points. As part of the physical examination, participants had a standardized musculoskeletal assessment to monitor ciprofloxacin toxic effects. Nutritional assessment included length (children ≤18 months) or height and weight. Spirometry data were collected in subjects 4 years or older who were able to perform the procedure.35 Age-appropriate audiometric testing was performed at 40 selected sites with the capability of performing the testing. Laboratory studies to assess safety included measurement of serum creatinine and serum urea nitrogen levels, liver function, and a complete blood cell count at baseline and every 6 months.
The primary clinical end point was the time to first PE requiring intravenous antibiotics or hospital admission during the 18-month study period. Since there is no validated definition of exacerbation in patients this age, we used an a priori–developed definition.30 The primary microbiological end point was the proportion of P aeruginosa –positive respiratory cultures among all quarterly cultures obtained after the initial treatment cycle.
Secondary clinical efficacy end points included (1) time to PE requiring any (intravenous, inhaled, or oral) antibiotic use or hospitalization, (2) anthropometric measures (linear growth, weight gain), and (3) pulmonary function test results (forced vital capacity, forced expiratory flow, and forced expiratory volume in 1 second). Evaluation of the safety profiles included adverse events, musculoskeletal symptoms, hearing acuity, hematological profile, and renal and liver function. In addition, emergence of antibiotic-resistant P aeruginosa and other significant pathogens was monitored.
The sample size for the clinical efficacy end point (time to first PE requiring intravenous antibiotics or hospitalization) was estimated based on the annual exacerbation event rate reported in the 1985-2000 Cystic Fibrosis Foundation National Patient Registry.30 There was a 50% difference in the annual exacerbation rate between children with new-onset P aeruginosa infection (0.36 per person-year) and children never infected with P aeruginosa (0.18 per person-year). A reduction in the exacerbation rate with more aggressive antibiotic therapy from 0.36 to 0.18 per person-year was assumed to be clinically meaningful. An 18-month study with 300 patients had 80% power to detect at least a 40% reduction in the risk of exacerbation in the cycled group as compared with the culture-based treatment group (primary comparison of interest) at the 2-sided α level of 5%. The design of this study also allowed comparisons between participants who received ciprofloxacin vs those who received placebo. Treatment interaction between cycled therapy and ciprofloxacin was also tested.
The randomization code was developed using a computer random-number generator to assign treatments within permuted blocks of size 12. Randomization assignment was available at the sites via an interactive voice response system with e-mail confirmation of the treatment assignment. Children remained on the same allocation throughout the study.
All study personnel and participants were blinded to oral therapy assignment but not to cycled or culture-based treatment allocation. The core study investigators were blinded to all treatment allocation for the entire study.
The intention-to-treat population was used for the primary efficacy and safety analyses (Figure 1). There was no imputation for missing values in secondary analyses and complete case analysis was performed. The censored failure time for the primary clinical efficacy analysis was the date of PE diagnosis, or the end of follow-up if no PE had occurred.30
Figure 1. Flow diagram of participants through each stage of the randomized trial. *One adverse event resulting in withdrawal was due to skin rash attributed to ciprofloxacin.
Hazard ratios and 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression, with covariate adjustment for baseline age group (1-3, >3-6, and >6 years). The age group–adjusted odds ratios (ORs) of a P aeruginosa– positive culture and 95% CI were estimated using generalized estimating equations with robust variance, specifying a logit link and assuming an independence working correlation structure.30
There was no interaction between cycled therapy and ciprofloxacin for the main study end points. Thus, the 2 main evaluations including cycled vs culture-based therapy and oral ciprofloxacin vs oral placebo are presented.
In secondary analyses, we evaluated time to PE requiring any antibiotics or hospitalization. Differences between groups in the linear rate of change from baseline in height and weight and spirometry results were tested using repeated-measures regression with robust variance estimation, with covariate adjustment for baseline age group.36 Differences in proportions were tested using a 2-sample test of proportions. Adverse events were descriptively summarized using the Medical Dictionary for Regulatory Activities system organ class and preferred term.
For all analyses, a 2-sided significance level of .05 was used without adjustment for multiple comparisons. All analyses were performed using the statistical software SAS version 9.1.3 (SAS Institute Inc, Cary, North Carolina) or R statistical package version 2.9.1 (R Foundation for Statistical Computing, Vienna, Austria).
Enrollment, conduct, and safety outcomes were monitored throughout the study by a Data and Safety Monitoring Board (see "EPIC Participating Centers and Investigators" box), with a formal safety report reviewed every 6 months.
A total of 337 children were screened for inclusion from December 2004 to February 2008 and 304 participants were randomized equally (n = 76) to each of the 4 treatment algorithms, received at least 1 dose of study drug (Figure 1), and were included in the intention-to-treat analysis. The follow-up was completed in June 2009. Over the study period, 3 to 8 participants withdrew from each treatment group (Figure 1). Follow-up visit completion, sample collection, and compliance with study medications were 90% or greater across treatment groups.
Participant baseline characteristics were well balanced across groups, including genotype status (Table 1 and
eTable 2). All participants had a P aeruginosa– positive culture within 6 months prior to randomization (week 0), and 46% received antimicrobial therapy during the 6 months preceding enrollment. At the time of randomization, 295 participants had a viable respiratory microbiology culture, with 118 (40%) P aeruginosa positive and 170 (58%) positive for Staphylococcus aureus (Table 1).
Following the first treatment cycle, the cycled and culture-based groups differed in treatment frequency during the study (Figure 2).
Figure 2. Percentage of participants prescribed treatment in the cycled and culture-based therapy groups.
Quiz Ref IDOverall, 24 of 152 (16%) in the cycled therapy group and 26 of 152 (17%) in the culture-based group experienced a PE requiring intravenous antibiotics or hospitalization. The hazard ratio (HR) of PE comparing cycled with culture-based therapy was 0.95 (95% CI, 0.54-1.66) (P = .86) (Figure 3A). Twenty-nine of 152 (19%) in the ciprofloxacin group and 21 of 152 (14%) in the placebo group experienced a PE requiring intravenous antibiotics or hospitalization (HR of PE, 1.45; 95% CI, 0.82-2.54; P = .20) (Figure 3B). Overall, the proportion of P aeruginosa– positive cultures was on average less than 20%. No statistically significant differences were seen in the odds of a P aeruginosa– positive culture comparing the cycled vs culture-based group (OR, 0.78; 95% CI, 0.49-1.23; P = .28) (Figure 3C) or the ciprofloxacin vs placebo group (OR, 1.10; 95% CI, 0.71-1.71; P = .67) (Figure 3D).
Figure 3. Efficacy outcomes. A, Proportion of participants remaining free of exacerbations requiring intravenous antibiotics or hospitalization over time, comparing participants who received cycled therapy (n = 152) with participants who received culture-based therapy (n = 152). B, Participants who received tobramycin inhalation solution (TIS) and oral ciprofloxacin (n = 152) compared with participants who received TIS and oral placebo (n = 152). C, Proportion of participants who were Pseudomonas aeruginosa positive at each study visit comparing participants who received cycled therapy (n = 152) with participants who received culture-based therapy (n = 152). D, Participants who received TIS and oral ciprofloxacin (n = 152) compared with participants who received TIS and oral placebo (n = 152).
The primary end points across all 4 treatment groups are in the
Seventy of 152 participants (46%) in the cycled therapy group vs 81 of 152 (53%) in the culture-based group experienced a PE requiring any (intravenous, inhaled, or oral) antibiotics or hospitalization (HR, 0.80; 95% CI, 0.58-1.11) (Table 2). Eighty-three of 152 participants (55%) in the ciprofloxacin group vs 68 of 152 participants (45%) in the placebo group experienced a PE requiring any antibiotics or hospitalization (HR, 1.29; 95% CI, 0.94-1.78) (Table 2).
The majority of participants had negative culture results throughout the study (Table 2), and among those who had positive results, the majority had no more than 2 P aeruginosa– positive cultures. The proportion of participants who had negative results at the end of the study in the cycle- and culture-based groups was not different. Emergence of mucoid strains of P aeruginosa appeared in 5 of 136 participants (3.7%) in the cycled arm and 6 of 143 (4.2%) in the culture-based arm and 6 of 141 (4.2%) vs 5 of 138 (3.6%) in the ciprofloxacin and placebo groups, respectively
(eTable 3). Overall, the emergence of tobramycin or ciprofloxacin resistance ranged from 0% to 4% across treatment groups without significant differences by treatment (eTable 3).
New isolation of other CF pathogens was not different across treatment groups. Although not different between groups, there was a nonnegligible new isolation of Stenotrophomonas maltophilia in 29 of 138 cycled-treated participants (21%) and 26 of 141 culture-based–treated participants (18.4%) and 29 of 137 (21.2%) vs 26 of 142 (18.3%) in the ciprofloxacin vs placebo group, respectively.
Age-adjusted longitudinal regression models for the estimation of the 18-month rate of change in height and weight showed no statistically significant differences between treatments (Table 2). Among participants able to perform spirometry, the 18-month rate of change in forced expiratory volume in 1 second showed no significant differences comparing the cycled (n = 73) vs culture-based (n = 70) groups or between the ciprofloxacin (n = 67) vs placebo (n = 76) groups (Table 2).
No significant differences in the occurrence of adverse events or serious adverse events were identified in the cycled vs culture-based arm (eTable 4), with the exception of participants assigned to oral ciprofloxacin (whether cycled or culture-based therapy), who demonstrated a greater frequency of symptoms of cough. Throughout the study, renal function, liver function, or blood cell counts were not statistically different among treatment groups. Likewise, no statistical differences were seen between groups in results of musculoskeletal examination (n = 304) or audiometric testing (n = 212).
Although several randomized trials demonstrated eradication of P aeruginosa from the respiratory tract of patients with CF who have recently acquired the bacterium,16-20 to our knowledge, the current study is the first to compare the effect of different therapeutic approaches. We found no statistically significant difference in terms of a reduction in PEs, growth rate, and pulmonary function between cycled quarterly TIS compared with treatment based on microbiological findings. Additionally, we were unable to detect differences in these clinical outcomes by adding a second antibiotic, oral ciprofloxacin. There was no difference in the proportion of P aeruginosa– positive cultures across the 4 treatment groups by the end of the study.
The study did not focus on a formal economic evaluation of treatment options, patient satisfaction, time spent receiving therapy, and overall burden to the family. However, participants randomized to the cycled therapy treatment arms received, on average, 5 additional 28-day treatment cycles of tobramycin or 280 additional inhalation treatments (15-20 minutes per treatment) over the 18 months compared with the culture-based group. Because there was no significant difference in hospitalizations or other measures of clinical benefit and given the low rates of exacerbations, it would be difficult to justify this additional treatment burden. This observation is supported by recent data suggesting that a single 28-day cycle is as effective as a 56-day cycle in clearing P aeruginosa from the airway, with a median time to recurrence of over 2 years.16 The present investigation focused extensively on the systematic evaluation of the safety profile of the different regimens and impact on bacterial resistance. The incidence of treatment-emergent resistance of P aeruginosa to tobramycin and ciprofloxacin was low, ranging from 0% to 4%. Because P aeruginosa recurrence was rare, it was not possible to test many isolates for antibiotic susceptibility. Although not different between groups, we observed emergence of a tobramycin-resistant, gram-negative pathogen S maltophilia in up to 20% of study participants. This frequency is concerning, but the clinical significance of this finding and this pathogen is unclear. S maltophilia has been observed in other studies of inhaled antibiotics,37 without suggestion of an accelerated decline in lung function, at least in older patients with CF chronically colonized with P aeruginosa.38 However, a recent study concluded that chronic S maltophilia detection in patients with CF is a risk factor for PEs.39
While not statistically significant, there was a trend toward more respiratory adverse events (increased cough) in participants assigned to receive ciprofloxacin. Considering that this finding was observed in the context of several secondary analyses, additional research is needed to address these potential concerns. Musculoskeletal adverse effects and hearing abnormalities were not increased.
Conduct of a large, randomized therapeutic trial in young children with CF was challenging. First, the duration of treatment and time commitment of families could have affected study attrition and study compliance. Fortunately, the attrition rate was remarkably low (<10%) and compliance with drug administration was excellent (>90%) in all treatment groups, minimizing bias from loss to follow-up or attenuation of effect size. Second, established clinical outcomes used in CF therapeutic trials involving older participants37,40,41 cannot be reproducibly collected in young children. For example, only 47% of study children were able to perform pulmonary function testing.35 Thus, forced expiratory volume in 1 second could not be used as a primary end point. In addition, only 6% of children were able to expectorate sputum, which is the optimal measure of lower airway infection.42 Thus, oropharyngeal cultures were collected to monitor microbiologic status, a method that is standard clinical practice in asymptomatic patients across the United States.43 We acknowledge that oropharyngeal cultures are a less sensitive measure of lower airway bacterial infection but we could not justify the increased risk or cost of repeated bronchoscopy in this population.44
Quiz Ref IDThe trial was conducted at multiple and widespread geographic sites across the United States, with a population enrolled in the study representing approximately 60% of all eligible patients in the United States.45 Despite enrolling a large proportion of eligible patients and allowing a long follow-up period, the study might have been unable to detect modest differences between the treatment arms. Nonetheless, this study remains one of the largest trials ever conducted in this young CF population. The rate of hospitalizations for respiratory symptoms was lower (0.17 person-year) than observed in the Cystic Fibrosis Patient Registry (0.36 person-year) during study planning. The lack of a placebo group limits our ability to detect a true effect of the study treatments. Over the past decade, the Cystic Fibrosis Foundation care guidelines have recommended quarterly microbiology cultures for all patients.43 This increased surveillance may have resulted in earlier institution of oral antibiotics for respiratory symptoms, affecting the frequency of respiratory-related hospitalizations. All antibiotic use for acute respiratory symptoms (87%) was higher than intravenous antibiotic (21%) administration, with no difference across groups. Two comparative groups are being analyzed for the primary end points, a historic control of children with CF enrolled in an epidemiology study46 from 1990 to 2000 with similar eligibility criteria and a concurrent cohort of patients who became P aeruginosa positive during this trial but chose not to enter the clinical trial.47
This report is an important step in understanding the optimal treatment of early P aeruginosa infection in CF. While not definitive regarding which treatment approach is optimal, the results of the trial provide well-controlled data and suggest little difference in clinical impact across treatment regimens. However, further understanding of the long-term clinical impact and safety of early antibiotic treatment will require additional studies. Study participants were enrolled in a 10-year observational study (89% enrolled) to collect long-term microbiologic, pulmonary function, growth, and hospitalization outcomes.
In conclusion, the approach of administering TIS at the time of recently documented isolation of P aeruginosa in the respiratory tract of children with CF resulted in similar success in maintaining participants free from PEs over an 18-month period, compared with a prophylactic antipseudomonal treatment strategy. Therefore, providing treatment based on a cycled, quarterly schedule is not supported by the results of this trial. The addition of oral ciprofloxacin did not confer additional protection with respect to PEs, microbiological eradication, or other clinical outcomes. These data also indicate that young children recently acquiring P aeruginosa have a high likelihood of eradication with antibiotic therapy and a prolonged period until reemergence of the pathogen. Based on these findings, judicious use of TIS with close microbiologic monitoring of airway cultures in young patients with CF recently infected with P aeruginosa is recommended.
Robert J. Beall, Preston W. Campbell III, Bruce C. Marshall.
Wayne Gabbert, Daniel Klein, Kevin Smith, Jim Stone.
Erica Crilly, Kwei Leong.
Lynne Quittell (chair), Columbia University; William R. Clarke, University of Iowa; Mary Jane Kennedy, Virginia Commonwealth University; Kenneth N. Olivier, National Institute of Allergy and Infectious Disease; Ronald C. Rubenstein, Children's Hospital of Philadelphia; O. Dale Williams, University of Alabama at Birmingham; Gail G. Weinmann, executive secretary, National Heart, Lung, and Blood Institute; Susan Banks-Schlegel, National Heart, Lung, and Blood Institute.
George Retsch-Bogart (chair), University of North Carolina at Chapel Hill; Susan Banks-Schlegel, National Heart, Lung, and Blood Institute; Robert J. Beall, Cystic Fibrosis Foundation; Preston W. Campbell, Cystic Fibrosis Foundation; Ron L. Gibson, University of Washington; Gavin R. Graff, The Penn State Milton S. Hershey Medical Center; Hector H. Gutierrez, The University of Alabama at Birmingham; Jamshed Kanga, University of Kentucky; Richard Kronmal, University of Washington; Robert Kuhn (ad hoc), University of Kentucky; Thomas Lahiri, Vermont Children's Hospital at Fletcher Allen Health Care; Nicole Mayer-Hamblett, University of Washington; Catherine McKeon, National Institute of Diabetes and Digestive and Kidney Diseases; Wayne Morgan, University of Arizona; Blakeslee E. Noyes, Saint Louis University/Cardinal Glennon Children's Medical Center; Bonnie W. Ramsey, University of Washington; Margaret Rosenfeld, University of Washington; Lisa Saiman (ad hoc), Columbia University Medical Center; Michael S. Schechter, Emory University; Dennis C. Stokes, Dartmouth-Hitchcock Medical Center; Jeffrey S. Wagener, The Children's Hospital; Judy Williams, CFFT Therapeutics Development Network Coordinating Center.
CRA/study monitors: Clare Castro, Deborah Chambers, Amy Feldman, Robin Hill, Tamara Potter, Sarah Velde; study managers: Shirley Desmon, Amanda Nelson, Judy Williams; clinical trials unit manager: Barbra Fogarty; data management: Barbara Mathewson, Trudi White; statisticians: Umer Khan, Steve Knutzen, Nicole Mayer-Hamblett; study pharmacist: Morty Cohen; quality assurance: Cheryl Kruesel, Dolores Seefried, Anna Wharton; network development: Natalie Beauchene, Lisya Van Housen; regulatory: Lynne Larson; finance: Donna Crist, Chris Fitzpatrick, Sherryl Singleton; microbiology core lab: Anne Marie Buccat, Jane Burns; medical monitors: Christopher Goss.
Akron Children's Hospital/Children's Hospital Medical Center of Akron, Akron, Ohio: site investigators (SI): Nathan C. Kraynack, Gregory Omlor, Kimberly A. Spoonhower; research coordinators (RC): Deborah A. Ouellette; Albany Medical College, Albany, New York: SI: Paul G. Comber; RC: Julie Pursel; Alfred I. duPont Hospital for Children, Wilmington, Delaware: SI: Aaron Chidekel; RC: Sandra M. Budd; All Children's Hospital, St. Petersburg, Florida: SI: Magdalen Gondor; RC: Stasia Lehmann; Children's Hospital Boston, Boston, Massachusetts: SI: Lindo Terry Spencer; RC: Erin Leone Thakkallapalli; Children's Hospital Los Angeles, Los Angeles, California: SI: Arnold C. G. Platzker; Children's Hospital of Michigan Wayne State University, Detroit: SI: Ibrahim Abdulhamid; RC: Catherine Van Wagnen; Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania: SI: David Orenstein; RC: Judy Fulton, Sandy Hurban; Children's Hospital of Wisconsin/Medical College of Wisconsin, Milwaukee: SI: William Gershan; RC: Tami Miller; Children's Hospitals and Clinics of Minnesota, Minneapolis: SI: Michael Pryor; RC: Sandy Landvik, Mary Sachs; Children's Memorial Medical Center, Chicago, Illinois: SI: Adrienne Prestridge; Children's Mercy Hospital, Kansas City, Missouri: SI: Philip Black; RC: Lora Bear; Cook Children's Health Care System, Fort Worth, Texas: SI: Maynard C. Dyson, Karen D. Schultz; RC: Sara Scott; Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire: SI: H. Worth Parker; Emory University, Atlanta, Georgia: SI: Michael S. Schechter; RC: Jeannette Peabody; Helen DeVos Children's Hospital, Grand Rapids, Michigan: SI: Susan L. Millard, John N. Schuen; RC: Teri L. Crumb, Tom Symington; Indiana University/Riley Hospital for Children, Indianapolis: SI: Michelle Howenstine; RC: Terry Barclay; Kaiser Permanente Medical Center, Oakland, California: SI: Greg Shay; RC: Julie Lee; Lucile Packard Children's Hospital/Stanford University, Palo Alto, California: SI: Richard Moss; RC: Colleen Dunn, Zoe Davies; Maine Medical Center, Portland: SI: Anne Marie Cairns, Thomas Mellow; RC: Mary Ellen Corrigan; Massachusetts General Hospital, Boston: SI: Allen Lapey; Medical College of Georgia, Augusta: SI: Margaret F. Guill, Katie McKie; Memorial Miller Children's Hospital, Long Beach, California: SI: Felice Adler-Shohet; RC: Nan O'Donnell; Monmouth Medical Center, Long Branch, New Jersey: SI: Robert L. Zanni; RC: Bridget Marra; Nationwide Children's Hospital, Columbus, Ohio: SI: Karen S. McCoy; Nemours Children's Clinic, Jacksonville, Florida: SI: David A. Schaeffer; RC: Donna L. Pingel, Rena A. Sprinkle; New York Medical College, Valhalla: SI: Nikhil Amin, Allen J. Dozor; RC: Ingrid Gherson; Oregon Health Sciences University, Portland: SI: Michael Wall; Rainbow Babies and Children's Hospital, Cleveland, Ohio: SI: Michael Konstan; RC: Colette Bucur, Cheryl Velotta; Seattle Children's, Seattle, Washington: SI: Ronald L. Gibson, Margaret Rosenfeld; RC: Sharon McNamara; St. Christopher's Hospital for Children, Philadelphia, Pennsylvania: SI: Laurie Varlotta; St Louis University/Cardinal Glennon Children's Medical Center, St Louis: SI: Blakeslee E. Noyes; RC: Vikki L. Kociela; Schneider Children's Hospital, New Hyde Park, New York: SI: Joan DeCelie-Germana; RC: Lynn Bonitz; SUNY Upstate Medical University, Syracuse, New York: SI: Ran D. Anbar; RC: Donna M. Linder, Valoree N. Suttmore; Texas Children's Hospital, Houston: SI: Peter W. Hiatt; RC: Charlene Hallmark; The Children's Hospital, Denver, Colorado: SI: Frank J. Accurso, Jeffrey S. Wagener; RC: Shelley A. Mann; The Children's Medical Center of Dayton/Wright State University, Dayton, Ohio: SI: Robert J. Fink, Gary A. Mueller; RC: Sandy R. Bartosik; The Johns Hopkins Medical Institutions, Baltimore, Maryland: SI: Peter J. Mogayzel Jr, Pamela L. Zeitlin; RC: Karen A. Callahan, Carolyn G. Chapman; The PennState Milton S. Hershey Medical Center, Hershey, Pennsylvania: SI: Gavin R. Graff, Michael S. Schwartz; RC: Lisa M. Allwein, Diane M. Kitch; The University of Alabama at Birmingham, Birmingham: SI: Hector H. Gutierrez; RC: Lacrecia Britton, Gina Sabbatini; University of California, San Francisco: SI: Dennis W. Nielson; RC: Diem Tran; University of Iowa, Iowa City: RC: Jean Frauenholtz, Mary Teresi; University of Kentucky College of Medicine, Lexington: SI: Michael I. Anstead, Jamshed F. Kanga; RC: Catherine Dudderar; University of Massachusetts Memorial Health Care, Worcester: SI: Brian P. O'Sullivan; RC: Dawn Baker; University of Michigan, Ann Arbor: SI: Samya Z. Nasr; University of Mississippi Medical Center, Jackson: SI: Kim Adcock; University of Nebraska Medical Center, Omaha: SI: John Colombo; RC: Dee Acquazzino; University of North Carolina at Chapel Hill: SI: George Retsch-Bogart; RC: Carol Barlow, Diane Towle; University of Rochester Medical Center, Rochester, New York: SI: Clement L. Ren; University of Tennessee Health Science Center, Memphis: SI: Robert A. Schoumacher; RC: Barbara A. Culbreath, M. Teresa Knight; University of Utah, Salt Lake City: SI: Barbara Chatfield; RC: Susan Griffiths; University of Virginia, Charlottesville: SI: Deborah K. Froh; RC: Robin Kelly; University of Wisconsin–Madison: SI: Michael J. Rock; RC: Linda Makholm; Vanderbilt Children's Hospital, Nashville, Tennessee: SI: Elizabeth Perkett; RC: Alice Bray; Vermont Children's Hospital at Fletcher Allen Health Care, Burlington: SI: Thomas Lahiri; RC: Sandra Diehl.
Correspondence: Miriam M. Treggiari, MD, PhD, MPH, Department of Anesthesiology and Pain Medicine, 325 Ninth Ave, Box 359724, Seattle, WA 98104 (firstname.lastname@example.com).
Accepted for Publication: April 8, 2011.
Author Contributions: Dr Treggiari had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Treggiari, Mayer-Hamblett, Kulich, Kronmal, Williams, Gibson, Burns, Rosenfeld, and Ramsey. Acquisition of data: Retsch-Bogart, Mayer-Hamblett, Hiatt, Gibson, Spencer, Orenstein, Chatfield, Froh, and Burns. Analysis and interpretation of data: Treggiari, Retsch-Bogart, Mayer-Hamblett, Khan, Kronmal, and Ramsey. Drafting of the manuscript: Treggiari, Retsch-Bogart, Mayer-Hamblett, Khan, Kronmal, Hiatt, Burns, and Ramsey. Critical revision of the manuscript for important intellectual content: Treggiari, Retsch-Bogart, Mayer-Hamblett, Kulich, Kronmal, Gibson, Spencer, Orenstein, Chatfield, Froh, Burns, Rosenfeld, and Ramsey. Statistical analysis: Mayer-Hamblett, Khan, Kulich, and Kronmal. Obtained funding: Treggiari, Mayer-Hamblett, Kronmal, and Ramsey. Administrative, technical, and material support: Retsch-Bogart, Hiatt, Gibson, Spencer, and Burns. Study supervision: Retsch-Bogart, Mayer-Hamblett, Williams, Hiatt, Gibson, Froh, and Ramsey.
Financial Disclosure: Study drugs and devices were supplied free of charge by Novartis Pharmaceutical Corp (TIS) and Bayer Healthcare AG (oral ciprofloxacin and oral placebo); compressors and nebulizers were provided by PARI Respiratory Equipment Inc. Dr Chatfield has had research grants or contracts from Gilead Pharmaceuticals, Vertex Pharmaceuticals, and the Cystic Fibrosis Foundation.
Funding/Support: The research for this article was supported in part by Cystic Fibrosis Foundation grant EPIC0K0, National Heart, Lung, and Blood Institute and National Institute of Diabetes and Digestive and Kidney Diseases grant U01-HL080310, and National Center for Research Resources grants ULI-RR025014-03, 1UL1-RR025744, 1UL1-RR025780, UL1-RR025005, UL1-RR0024979, UL1RR025747, UL1-RR025011, 1UL-RR024975, and M01-RR02172.
Role of the Sponsor: The industry sponsors had no role in the analysis, interpretation, and writing of the manuscript. The National Heart, Lung, and Blood Institute–appointed Data and Safety Monitoring Board played a role in the conduct, collection, management, analysis, and interpretation of the data and reviewed and approved the final manuscript.
This article is featured in the Archives Journal Club. Go here to download teaching PowerPoint slides.
Additional Contributions: Special thanks to families of children with CF who participated in the study and whose dedication to research made the trial possible. Patricia Roush, AuD, provided guidance and consultation on audiometric testing. She received financial compensation for her work.
eTable 1. Overview of treatment strategies in the randomized trial.
eTable 2. Participant baseline characteristics by treatment interaction.
eTable 3. Percent of participants with resistant Pseudomonas aeruginosa at baseline
(Week 0) and percent with emergence* of resistance during the 70 week follow-up.
eTable 4. Overview of hospitalizations and serious adverse events by system organ class.
eFigure. Proportion of participants remaining free of exacerbations requiring intravenous antibiotics or hospitalization over time, comparing (a) participants who received cycled TISciprofloxacin (solid line, N=76), participants who received cycled TIS-placebo (dash line, N=76), participants who received culture-based TIS-ciprofloxacin (dotted line, N=76), and participants who received culture-based TIS-placebo (dash-dot line, N=76. The interaction effect of inhaled tobramycin and oral ciprofloxacin was not significant from the age-adjusted Cox Proportional Hazards model for time to exacerbations requiring IV antibiotics (p-value=0.56); (b) Proportion of participants who were Pa positive at each study visit comparing participants who received cycled TIS-ciprofloxacin (black bars, N=76), participants who received cycled TIS-placebo (dark gray bars, N=76), participants who
received culture-based TIS-ciprofloxacin (light gray bars, N=76), and participants who received culture-based TIS-placebo (white bars, N=76).
Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, et al. Comparative Efficacy and Safety of 4 Randomized Regimens to Treat Early Pseudomonas aeruginosa Infection in Children With Cystic Fibrosis. Arch Pediatr Adolesc Med. 2011;165(9):847–856. doi:10.1001/archpediatrics.2011.136
© 2023
Artificial Intelligence Resource Center


text:
Home » Classic in Field » DIDKOVSKY/MACLEAN/VRTACEK: Flies in the Face of Logic
DIDKOVSKY/MACLEAN/VRTACEK: Flies in the Face of Logic
Pieces by the 3 characters above for virtual and real pianos, sampled, treated, prepared and reconstructed pianos and one dropped from a crane from 100 feet.The Maclean pieces I have to single out for special mention- work of exquisitely integrated conception. performance, construction and subsequent manipulation; this is close to perfection by earthly standards. A lot of invention, thinking and pragmatics all round. Appropriately, 'None of us play piano. This is a common obstacle we shared, took advantage of and each dealt with in our own way' L
Code: POGUS21008-
Price: £14.50


text:
I had an email sent to me just now and thought I would post it! I have seen this before, but never tried it...seems easy enough? If you decide to try it, leave a comment and let us know how it turned out and what kind you tried! Here's what you need to get started:
- 4 tablespoons flour
- 4 tablespoons sugar
- 2 tablespoons cocoa
- 1 egg
- 3 tablespoons milk
- 3 tablespoons oil
- 3 tablespoons chocolate chips (optional)
- A small splash of vanilla extract
- 1 large coffee mug (MicroSafe)
- Add dry ingredients to mug, and mix well
- Add the egg and mix thoroughly
- Pour in the milk and oil and mix well
- Add the chocolate chips (if using) and vanilla extract, and mix again
- Put your mug in the microwave and cook for 3 minutes at 1000 watts.
The cake will rise over the top of the mug, but don't be alarmed! Allow to cool a little, and tip out onto a plate if desired. EAT ! (this can serve 2 if you want to feel slightly more virtuous).
What mother wouldn't love it?


text:
Username or email *
Password *
Log in
Showing 1–24 of 47 results
These cookies are necessary for the proper operation of our website and for the user to navigate and use its features such as access to secure areas of the site. Without these cookies, some of the site's services and features, such as a shopping cart or an electronic payment, can not be provided.
These cookies collect information about how visitors use the web page, for example which pages they visit more often, and whether they are receiving bugs from webpages. These cookies do not collect information that identifies the visitor. All information collected by these cookies is aggregated and therefore anonymous. They are only used to improve the way the site works.
[ Placeholder content for popup link ]
WordPress Download Manager - Best Download Management Plugin


text:
Product Details
Vision LED Stop / Tail Light Bulbs by Philips®. Replace your standard car lights with long-lasting Philips Vision LED lights. They are a direct replacement for incandescent bulbs and are resistant to extreme heat and high vibrations. One look at their advanced design tells you these lights are like nothing you have seen before – Vision LED lights have been designed to outlast your car! And they are backed by 12-year limited warranty. Standard incandescent bulbs actually take a little time to light up. But Vision LED lights turn on instantly. That means, when you brake, the vehicle behind you can react sooner. The instant-on response provided by Vision LED lights can reduce braking distance by up to 20 ft. at a speed of 75 mph. Now that is an advantage every driver can use.
Impervious to high vibrations
Expected to efficiently operate in high shock and high vibration environments.
Heat resistant
Thoroughly designed to be able to withstand the exposure to moderately hot temperatures without damage.
Sustainable lighting solution
Developed to provide extremely bright illumination for your ultimate satisfaction.
Wide beam angle
Bulbs have a wide beam angle which ensures maximum coverage and allows for greater visibility.
Vision LED bulbs last 12 years, guaranteed
Covered by a 12-year limited warranty, Vision LED bulbs have been designed to outlast your auto.
Replace your factory bulbs with powerful Philips Vision LED bulbs which deliver dynamic lighting for your vehicle. They reflect a leading innovation in the field of illumination. Featuring a groundbreaking design and delivering unsurpassed performance, Philips Vision LEDs bulbs are just second-to-none. Made with durability in mind, the bulbs provide extreme resistance to extreme temperatures and high vibrations. And thanks to a great lifespan, you will likely never have to replace them again. Moreover, all of the bulbs are backed by a 12-year limited warranty. With Vision LED bulbs, your lighting will be on the cutting edge now and for years to come.
Philips® is a global leader in the areas of Consumer Electronics, Healthcare and Lighting. The company was founded in late 1891 to manufacture reliable incandescent lamps and other electrical products and make them affordable for everyone who needed them. Over a century later, Philips is still committed to improving the lives of people around the world, providing forward-thinking technologies and innovative solutions ranging from award-winning computer monitors and digital voice recorders to automotive bulbs and audio electronics.


text:
Privacy Policy
Your privacy is important to us. This Privacy Policy describes our practices with respect to (i) the personal information we gather on our website (ii) the way we use personal information internally; and (iii) our policy regarding sharing your personal information with others.
We are committed to processing your information in accordance with international legal standards, including the General Data Protection Regulation (GDPR) and other applicable data protection laws and data protection codes of conduct. We have implemented the practices set out in this Privacy Policy for our website and dependent pages (the "Site"). We have instructed our website administrator to include information regarding these privacy practices anywhere on the Site where Personal Information is collected.
This policy addresses our privacy practices relating to visitors to the Site and registered users of the Site. For purposes of this Privacy Policy, "Personal Information" means any information that, by itself or in combination with other information, identifies or can reasonably be used to identify an individual, such as name, email address, IP address, telephone number, address, billing information or date of birth. Personal Information does not include information that is anonymized or publicly-available information. The term "Processing" means any operation or set of operations which is performed on Personal Information, whether or not by automated means, such as collection, use, organization, storage, alteration or destruction, disclosure, or transfer.
Declaration of Consent
By submitting Personal Information and other information to the Site, you consent to the Processing of such information in accordance with the terms of this Privacy Policy.
You may withdraw this consent at any time by filling out the withdrawal consent form, notifying us at email@example.com, or by writing to Media Cybernetics, 1700 Rockville Pike, Suite 240, Rockville, MD 20852, United States.
Collecting Company Information
Generally, you may browse the Site without providing any Personal Information. However, we may ask that you provide information, including, without limitation, Personal Information, at various times and locations through the Site. For example, if you decide to register with the Site to request information, you will be asked to provide information such as your name and email address. When using forms on the Site to communicate with us, you may choose to provide other Personal Information, such as your name, company name, mailing address, phone number, and email address. We may collect and store any Personal Information you input into the Site.
Protecting Personal Information
How We Use Personal Information
- contact you about the Site;
- notify you about important changes to the Site;
- evaluate products or services we could offer to you;
- monitor or improve use of the Site;
- compare and otherwise use data entered by users for any purpose including consulting, research and marketing;
- customize any advertising and content you see on the Site;
- provide specific information to you from us and/or our affiliates; and
- send you promotional material from us and/or our affiliates.
Corrections & Requests for Personal Information or Erasure of Personal Information
If you want us to correct your Personal Information or other information, or if you would like us to provide you with a copy of the Personal Information that we hold about you, or if you would like the Personal Information that we hold about you to be erased, please contact us by sending us an email at firstname.lastname@example.com or by writing to us at Media Cybernetics, 1700 Rockville Pike, Suite 240, Rockville, MD 20852, United States.
We will respond to any such requests within 30 days of receipt.
Personal Information Retention
Personal Information will be stored for as long as the information is required to fulfill our legitimate business needs or the purposes for which the Personal Information was collected, or for such period as is required by law.
Data Transfers to Countries Outside the EU/EEA
Data entered on our website are transferred to a server in the U.S. and stored there. Your data may be used (see previous section "How We Use Personal Information") by the Company and its divisions, holding companies, subsidiaries and affiliates, or other entities outside the European Union (EU) and the European Economic Area (EEA) including in the U.S. Please note that in countries outside the country in which you live, and in particular outside the EU/EEA, a different standard of data protection might apply than the standard that you are used to in your own country. By completing and submitting the contact form on our website, you acknowledge and consent that data will be transferred across international borders, including to countries outside the EU/EEA.
Disclosing Personal Information to Third Parties
Any Personal Information that you provide to us will be used for our purposes only. Personal Information will not be shared with individuals or other companies other than those referred to in this Privacy Policy. In some instances, however, we may need to provide Personal Information to third parties that we use to deliver specific products or services to you (such as shipping or direct mailing organizations). In such cases, our agreements with these third parties do not permit them to use Personal Information for purposes other than fulfilling those services or allow such third parties to further disclose your Personal Information.
Domain Name & IP Address
We collect the domain names and IP addresses of our visitors for statistical purposes, to measure use, to improve the content or responsiveness of the Site, or to customize the content or layout of the Site for the individual visitor. We do not disclose this information to third parties. We may also aggregate information relating to our visitors' traffic patterns from the data that we collect and retain concerning the IP addresses and domain names of our visitors, and we may divulge such aggregate information about our users with third parties such as our business partners, distributors, and service and support providers.
Log Files
We maintain a log file of all actions that are initiated or facilitated using the Site, to capture, record and store data concerning the transaction. Access to this data is restricted to those who administer our network and public website, except that we may use and disclose this information to third parties in response to legal process or law enforcement inquiries, abuse of our website, or violation of any applicable Terms of Use or contractual provision you may have with us.
E-mail Addresses
You should know that e-mail is not necessarily secure against all forms of interception. If your communication includes sensitive information about your company and you would prefer not to transmit this information in this fashion, please contact us by post or telephone rather than e-mail.
We collect email addresses that are: volunteered by the visitor; through e-mail messages addressed to us or our employees; through visitor responses via the "contact us" portion of the Site; or e-mail marketing destination web pages and public events. We use e-mail addresses for marketing purposes and to inform those interested in our products about events, products, services or other items of interest. We may also use e-mail addresses volunteered by our visitors to register the visitor for an extranet account, to process orders for brochures and other written materials, or otherwise to respond to a visitor's request.
On the Site we will ask you to consent to being contacted by us for promotional and marketing purposes. However, you may opt-out of receiving promotional or marketing emails at any time by notifying us as a reply to any unwanted e-mail, by using the unsubscribe function in our website, contacting us at firstname.lastname@example.com, or by writing to Media Cybernetics, 1700 Rockville Pike, Suite 240, Rockville, MD 20852, United States. Requests to unsubscribe from Media Cybernetics e-mails may take 5 business days to process.
A cookie is an element of data that a website can send to your browser, which may then be stored on your system. You can set your browser to notify you when you receive a cookie, giving you the chance to decide whether to accept it. We use one type of cookie to maintain your login information for as long as you are using the Site. No Personal Information is stored in this cookie and the cookie is deleted from your computer when you leave the Site. Our second cookie type simply identifies you as you move throughout the Site, providing faster, personalized access to view various site pages.
Google Analytics
This website uses Google Analytics, a web analytics service provided by Google, Inc. ("Google").
Google Analytics uses "cookies", which are text files placed on your computer, to help the website analyze how users use the site. The information generated by the cookie about your use of the Site (including your IP address) will be transmitted to and stored by Google on servers in the U.S. If the IP anonymization is activated, Google will truncate/anonymize the last octet of the IP address for Member States of the European Union as well as for other parties to the Agreement on the European Economic Area. In exceptional cases, the full IP address is sent to and shortened by Google servers in the U.S.
On behalf of the website provider Google will use this information for the purpose of evaluating your use of the Site, compiling reports on website activity for website operators and providing other services relating to website activity and internet usage to the website provider. Google will not associate your IP address with any other data held by Google.
You may refuse the use of cookies by selecting the appropriate settings on your browser. Furthermore, you can prevent Google's collection and use of data (cookies and IP address) by downloading and installing the browser plug-in available under
Google Cookie Browser extension
Further information concerning the terms and conditions of use and data privacy can be found at:
Google's International Policies
Please note that on this website, Google Analytics code is supplemented by "anonymizeIp" to ensure an anonymized collection of IP addresses within the EU and EEA (IP-masking)].
Third-Party Sites
The Site may contain links to other third-party sites. When you click on one of these links you are visiting a website operated by someone other than us and the operator of that website may have a different privacy policy. We are not responsible for their individual privacy practices, so we encourage you to investigate the privacy policies of such third-party operators.
Our website is not intended for children under 13 years of age. No one under age 13 may provide any information to us through the Site. We do not knowingly collect Personal Information from children under 13. If you are under 13, do not access, use, or provide any information on the Site or on or through any of its features. If we learn we have collected or received Personal Information from a child under 13 without parental consent, we will delete that information. If you believe we might have any information from or about a child under 13, please contact us by sending us an email at email@example.com or writing to us at Media Cybernetics, 1700 Rockville Pike, Suite 240, Rockville, MD 20852, United States.
Data Breaches
Whilst every effort and measure is taken to reduce the risk of data breaches, we have dedicated controls and procedures in place for such situations, along with the procedures that are required to make notifications to the relevant Supervisory Authority and data subjects (where applicable).
Comments & Questions
We welcome comments and questions regarding this Privacy Policy. Any such questions should be directed via e-mail to firstname.lastname@example.com. Additionally, you may make your request in writing to Media Cybernetics, 1700 Rockville Pike, Suite 240, Rockville, MD 20852, United States.


text:
Regular price $8.00
Unit price
2.25 inch diameter one single gameday button
- $10 flat rate shipping for orders under $150
- FREE on orders over $150!
- Orders are processed and shipped out within 72 hours.
- FREE local pickup is available in Columbia, South Carolina (choose option at checkout.)
- Returns on unworn, unwashed items with tags still attached are accepted within 14 days of receipt of item.
- Returns are eligible for store credit only.
- Sale/clearance items are NOT returnable, they are final sale.
- Shipping charges (original and return) are the customer's responsibility.
- Please fill out the form below to initiate your return (if eligible):


text:
Download here the national salvadoran flag in a very modern and design view.
4 sizes are available for your purpose : S, M, L, XL.
Flag of El Salvador: The National Salvadoran Flag
Any use of our flags on the web has to lead to a link to this page :
If the use is made in the context of a site generating income, or for the purpose of generating income, a DMCA statement (Digital Millennium Copyright Act) will be filed.


text:
Why choose Sprowls City Appliance & TV?
→ Great prices on top brands
→ The best selection of Appliances, Electronics and Home Furnishings
→ Friendly, helpful and knowledgeable salespeople
→ Professional installation and service.
Sprowls City Appliance & TV carries a large selection of Appliances, Electronics and Home Furnishings including refrigerators, cooktops, oven, ranges, washing machines, dryers, TVs, living furniture, bedroom furniture and more. If you are looking for appliances, electronics or home furnishings in the area, be sure to shop at Sprowls City Appliance & TV. And before you go to their showroom be sure to check out Sprowls City Appliance & TV special offers - discounts, rebates, and financing specials on top brand merchandise (e.g. Amana, Maytag).
Sprowls City Appliance & TV is part of the Brandsdirect network of independent dealers. Brandsdirect dealers offer their customers the best names in brand appliances, furniture and electronics through the nation's single largest network of independent stores. Brandsdirect have a store close to you with knowledgeable local sales people.
Sprowls City Appliance & TV is the right choice for the discriminating shopper.


text:
We've provided this Privacy Policy, which sets forth our terms regarding the collection, use and protection of the personal information of those using the Tedarla Properties Inc website. Personal information means information that can be linked to a specific individual, such as name, address, ip address, telephone number, e-mail address and credit card number.
We encourage you to review our Privacy Policy, and become familiar with it, but you should know that we do not sell or rent our customers' personal information to any third parties.
Please note that we review our Privacy Policy from time to time, and we may make periodic changes to the policy in connection with that review. Therefore, you may wish to bookmark this page and/or periodically review this page to make sure that you have the current version.
This Privacy Policy explains the following:
What personal information does Tedarla Properties Inc gather from me and how is this When browsing our site, you are not required to provide any personal information unless and until you choose to make a purchase or sign up for one of our e-mail newsletters or other services as described below. We do not knowingly permit the site to be used by any person under the age of eighteen and we do not knowingly collect any personal information from children (meaning those younger than thirteen years of age).
Making a Purchase
In order to purchase travel and related services through our site, you must provide us with certain personal information such as your name, your credit card number and expiration date, your credit card billing address, your telephone number, your e-mail address and the name or names of the person(s) traveling.
Member Registration
If you choose to become a registered member of tedarlapropertiesinc.propertywaresites.com, you must provide your name, e-mail address, a unique login name and password. Other information may be collected on a voluntary basis. As a tedarlapropertiesinc.propertywaresites.com member you will also occasionally receive updates from us about fare sales in your area, special offers, new Tedarla Properties Inc services, and other noteworthy items. However, you may choose at any time to no longer receive these types of e-mail messages. By supplying a phone number, it is implied that you are giving us consent to contact you regardless if the phone number is listed in any "Do not call" lists.
Member Profile
As a tedarlapropertiesinc.propertywaresites.com member, you can choose to complete your online profile by providing us with travel preferences. This information is primarily used to assist us in finding the most suitable travel deal for you. With your login and password, you can at anytime update or remove supplied information.
Automatic Logging of Session Data
We automatically log generic information about your computer's connection to the Internet, which we call "session data". Session data consists of things such as IP address, operating system and type of browser software being used and the activities conducted by the user while on our site. An IP address is a number that lets computers attached to the Internet, such as our web servers, know where to send data back to the user, such as the pages of the site the user wishes to view. We collect session data because it helps us analyze such things as what items visitors are likely to click on most, the way visitors are clicking through the site, how many visitors are surfing to various pages on the site, how long visitors to the site are staying and how often they are visiting. It also helps us diagnose problems with our servers and lets us better administer our systems. It is possible to determine from an IP address a visitor's Internet Service Provider (ISP) and the approximate geographic location of his or her point of connectivity. We may also use some session data, such as the pages you visited on our site, to send you e-mail unless you had previously opted out of receiving such messages.
"Cookies" are small pieces of information that are stored by your browser on your computer's hard drive. There are many myths circulating about cookies, but you should know that cookies are only read by the server that placed them, and are unable to do such things as run programs on your computer, plant viruses or harvest your personal information. The use of cookies is very common on the Internet and tedarlapropertiesinc.propertywaresites.com's use of cookies is similar to that of such sites as Expedia and Travelocity, as well as Google, CNN.com and other reputable online companies.
First and foremost, you can rest assured that no personal information about you is gathered or stored in the cookies placed by the tedarlapropertiesinc.propertywaresites.com website and, as a result, none can be passed on to any third parties.
Cookies allow us to serve you better and more efficiently, and to personalize your experience at our site.
A cookie may also be placed by our advertising server. Such cookies are used only for purposes of tracking the effectiveness of advertising served by us on our site and no personal information about you is gathered from you by the use of these cookies, nor is this information shared with any third parties. Similarly, a cookie may be placed by our third-party advertising companies. These companies may use aggregated statistics about your visits to this and other web sites in order to provide advertisements about travel-related goods and services that you may be interested in. The information they collect does not include your personal information.
The third-party advertising companies may also employ technology that is used to measure the effectiveness of ads. Any such information is anonymous. They may use this anonymous information about your visits to this and other sites in order to provide advertisements about goods and services of potential interest to you. No personal information about you is collected during this process. The information is anonymous and does not link online actions to an identifiable person.
Most web browsers automatically accept cookies. Of course, by changing the options on your web browser or using certain software programs, you can control how and whether cookies will be accepted by your browser. Tedarla Properties Inc supports your right to block any unwanted Internet activity, especially that of unscrupulous websites. However, blocking tedarlapropertiesinc.propertywaresites.com cookies may disable certain features on our site and may make it impossible to purchase or use certain services available on the site. Please note that it is possible to block cookie activity from certain web sites while permitting cookies from sites you trust, like tedarlapropertiesinc.propertywaresites.com.
From time to time we may add or enhance services available on the site. To the extent these services are provided and used by you, we will use the information you provide to facilitate the service requested. For example, if you email us with a question, we will use your email address, phone number, name, nature of the question, etc. to respond to your question. We may also store such information to assist us in making the site the better and easier to use.
Remarketing List:
Tedarla Properties Inc implemented and use Display Advertising. The Google Analytics features we've implemented are based on Displayed Advertising (e.g., Remarketing). Visitors can opt-out of Google Analytics for Display Advertising and customize Google Display Network ads using the Ads Preferences Manager.
Tedarla Properties Inc uses Remarketing with Google Analytics to advertise online. Third-party vendors, including Google, show your ads on sites across the Internet.
Tedarla Properties Inc and third-party vendors, including Google, use first-party cookies (such as the Google Analytics cookie) and third-party cookies (such as the DoubleClick cookie) together to inform, optimize, and serve ads based on someone's past visits to your website.
Thank you for using tedarlapropertiesinc.propertywaresites.com!


text:
MIIS Students Visit Haiti to Implement Teacher Training Curriculum Designed in Class
In October of this year, Monterey Institute staff member Lisa Donohoe Luscombe (MATESOL '09) traveled to St. Andre's school in the central plateau of Haiti on a volunteer mission to conduct an English language needs analysis for the 900-student school and to introduce One Laptop Per Child XO machines to teachers and students. The project, nicknamed "Team EFL Haiti," attracted a team of four students in the fall curriculum design course led by Professor Jason Martel.
The students—Haley Berl (MATESOL '14), Dane Carson (MATESOL '16), Maggie Rodgers (MATESOL '16) and Syd Schulz (TESOL Certificate '13)—developed a curriculum design for both English and computer literacy at St. Andre's. In January over winter term, Haley, fellow student Gregory Singfield (MATESOL '14) and alumna Marie Snider (MATESOL '13) traveled to Haiti to work on a three-week project that included teaching evening English classes for the community, working with local English teachers on teacher training and professional development, and setting up a computer lab for students.
As far as real-life professional training goes, it does not get much better than this. The students have all worked exceptionally hard, knowing that their class project can make an immediate difference in people's lives. Being able to follow up and implement the first phase of the curriculum is another amazing learning experience. In the evening, when the team in Haiti has a few moments to unwind, they use it to hang out with members of the community, laughing and talking into the night. They are dutifully recording their experiences on a blog and will share their reflections and lessons learned with fellow students when they return.
And this is just the beginning—starting in the spring semester, a new group of students will begin developing an official English language curriculum for St. Andre's school.
For More Information
Jason Warburg
Eva Gudbergsdottir


text:
You are here: Front page > Denmark > Southeast Jutland and Als > Flensborg Fjord
Use our easy search system below to find a holiday home in just the area, you are looking for. You can filter your search and choose e.g. ocean views, pool, dish washer and internet.
See all houses in the area.


text:
Skip to Main Content
Do Not Show Again
Create a Website Account
- Manage notification subscriptions, save form progress and more.
Website Sign In
Benefits & Compensation
Forms & Policies
How Do I...
Workforce Development
Civil Service Commission
To add one of the following iCalendar feeds to your calendar:
Right click on the calendar that interests you and select Copy Shortcut. This will copy the link to your clipboard.
Paste the link into the appropriate area of your calendar program.
Main Calendar
What is iCalendar?
iCalendar allows users to import internet calendars and/or events into their personal calendar applications. You can add a single event to your calendar by selecting the iCal icon, downloading the file and importing it into your calendar program of choice. You can also subscribe to the entire calendar if you want your calendar to automatically update the calendar as events are added on the website.
Sample programs that use the iCal format include:
Microsoft Outlook
Apple iCal
Google Calendar
Most Smartphone Desktop Applications
▲ Back to top
Live Edit
Arrow Left
Arrow Right
Slideshow Left Arrow
Slideshow Right Arrow


text:
Privacy Policy
MOFF Hawaii Corporation is committed to protecting your privacy and ensuring that your personal information is handled in a safe and responsible way. This policy outlines how we aim to achieve this and includes the information collected when:
- you use our website https://moff-usa.com/.
- you place an order on our website.
- you make inquiries on our website.
- someone is interested in working with us.
Definition of Personal Data
Personal Data means any data that relates to an identifiable person who can be directly/indirectly identified from that data. In this case, it means personal data that you give to us via our site.
By providing your personal data, you agree that we can use your personal data in accordance with this policy.
Ensure you understand this policy in its entirety and take your time to read it.
Who are we?
MOFF Hawaii Corporation is a cafe/venue based at 2330 Kalakaua Avenue, Honolulu, HI 96815
We are part of a group of MOFF Corporation
Our registered address is 2330 Kalakaua Avenue, Honolulu, HI 96815.
How do we collect information from you?
We collect information from you:
- when you place an order
- when you visit a cafe (preferences, allergies etc.).
- make an inquiry.
- when you sign up for marketing emails.
What type of information is collected from you?
You may be asked to submit personal information about yourself when you place an order. We will collect this information so we can fulfill your ordering request.
When you place an order:
MOFF Hawaii Corporation collects information such as:
- title
- name
- e-mail address (used for ordering confirmation and post-dining feedback emails)
- home or work address
- billing information taken for deposits, ticketing, or holding credit card information for
use in the case of no-shows (where applicable)
- telephone number
- company name
- dietary requests
- marketing preferences (whether you opt-in or opt-out)
When you dine at Cat Café MOFF:
- marketing responses
- survey responses
- current and past company reservation details
When you access our sites:
There is "Device Information" about your computer hardware and software that is automatically collected by MOFF Hawaii Corporation This information can include:
- device type (e.g. mobile, computer, laptop, tablet)
- cookies
- operating system
- IP address
- browser type
- browser information (e.g., type, language, and history)
- domain names
- access times
- settings
- referring website addresses
- other data about your device to provide the services as otherwise described in this policy.
Location information:
If you use our website, we may receive your generic location (such as city or neighborhood).
You may submit your CV if you're interested in working for us to firstname.lastname@example.com. This information may include:
- personal details
- employment details
- education
- salary history
- other relevant details
We will use this information to assess your application. We may also keep it in our records for future reference. Please get in contact if you would no longer like us to hold your records at email@example.com.
How is your information used?
Our use of your personal data will always have a lawful basis, either because it is necessary to complete orders because you have consented to our use of your personal data (e.g. by subscribing to emails), or because it is in our legitimate interests.
We require the information outlined in the previous section to understand your needs and provide you with a better service, and in particular for the following reasons:
- Internal record keeping.
- Send you service emails (order confirmation and post-dining feedback).
- Improve our products and services.
- Send marketing communications if you have opted in to receive them.
- We may use the information to customize the website according to your interests.
Who has access to your information?
We will not sell, distribute, or lease your personal information to third parties. Any personal information we request from you will be safeguarded under current legislation.
We will only share your information with companies if necessary to deliver services on our behalf. For example, service providers, third-party payment processors, and other third parties to provide our Sites and fulfill your requests, and as otherwise consented to by you or as permitted by applicable law.
Third parties whose content appears on our Site may use third-party Cookies, as detailed below. Please refer to 'Use of Cookies' for more information on controlling Cookies. Please note that we do not control the activities of such third parties, nor the data they collect and use, and advise you to check the privacy policies of any such third parties.
You may choose to restrict the collection or use of your personal information at any point. Please refer to the Your Choices section of this Privacy Policy for details.
How and where do we store data?
We only keep your personal data for as long as we need in order to use it as described in this privacy policy, and/or for as long as we have your permission to keep it.
We may analyze your personal information to create a profile of your interests and preferences so that we can contact you with information relevant to you. We may make use of additional information about you when it is available from external sources to help us do this effectively.
Your choices
We will not contact you for marketing purposes by email, phone or text message unless you have given your prior consent. We will not pass your details to any third parties for marketing purposes unless you have expressly permitted us to. Furthermore, you can change your marketing preferences at any time by contacting us by email at firstname.lastname@example.com.
You have a right to request a copy of the personal information that MOFF Hawaii Corporation holds about you and have any inaccuracies corrected. Any such requests should be made to this email address: firstname.lastname@example.com.
You have the right to withdraw your consent to us using your personal data at any time, and to request that we delete it. We do not keep your personal data for any longer than is necessary in light of the reason(s) for which it was first collected. Data will, therefore, be retained for the following periods (or its retention will be determined on the following basis):
Data security is very important to us, and to protect your data we have taken suitable measures to safeguard and secure data collected through our Site.
Use of 'cookies'
Like many other websites, we use cookies. We use them to help you personalize your online experience.
A cookie is a text file that is placed on your hard disk by a web page server which allows the website to recognize you when you visit. Cookies only collect data about browsing actions and patterns, and do not identify you as an individual.
We use cookies for the following purposes:
- Authentication, personalization and security: cookies help us verify your account and device and determine when you log in, so we can make it easier for you to access the services and provide the appropriate experiences and features. We also use cookies to help prevent fraudulent use of login credentials.
- Performance and analytics: cookies help us analyze how the services are being accessed and used, and enable us to track the performance of the services. For example, we use cookies to determine if you viewed a page or opened an email. This helps us provide you with information that you find interesting. We also use cookies to provide insights regarding your End Users and your sites' performance, such as page views, conversion rates, device information, visitor IP addresses, and referral sites.
- Third Parties: Third Party services may use cookies to help you sign into their services from our services. We also may use third-party cookies, such as Google Analytics, to assist with analyzing performance. Any third party cookie usage is governed by the privacy policy of the third party placing the cookie.
- Opting Out: You can set your browser to not accept cookies, but this may limit your ability to use the services.
Our Site may contain links to other websites. Please note that we have no control over how your data is collected, stored, or used by other websites and we advise you to check the privacy policies of any such websites before providing any data to them.
What happens if our business changes hands?
We may, from time to time, expand or reduce our business and this may involve the sale and/or the transfer of control of all or part of our business. Any personal data that you have provided will, where it is relevant to any part of our business that is being transferred, be transferred along with that part. The new owner or newly controlling party will, under the terms of this Privacy Policy, be permitted to use that data only for the same purposes for which it was originally collected by us.
In the event that any of your data is to be transferred in such a manner, you will (NOT) be contacted in advance and informed of the changes. (When contacted you will (NOT, HOWEVER,) be given the choice to have your data deleted or withheld from the new owner or controller.)
Company groups
We may share your information (such as meal or seating preferences and special occasions) with other companies in our same company group. This is to enhance the hospitality experience that we (the company group) provide you when you dine with us (such as, trying to seat you by a window, if you previously expressed a preference for window seating) ("customized service") and to improve our table and shift planning.
In addition to providing you with more customized service, we may, as permitted by applicable law, share your information with our company affiliates to support operations, such as to perform analytics, tailor marketing to you, support a loyalty program that you have chosen to participate in, and improve services.
For more information, please feel free to contact us at email@example.com
Changes to this statement
MOFF Hawaii Corporation will occasionally update this Privacy Policy to reflect company and customer feedback. MOFF Hawaii Corporation encourages you to periodically review this statement to be informed of how MOFF Hawaii Corporation is protecting your information. This policy was last updated in June 2023.
Contact Information
MOFF Hawaii Corporation welcomes your comments regarding this Privacy Policy. If you believe that MOFF Hawaii Corporation has not adhered to this Privacy Policy, please contact MOFF Hawaii Corporation at email@example.com. We will aim to use commercially reasonable efforts to promptly determine and remedy the problem.


text:
Create a Website Account - Manage notification subscriptions, save form progress and more.
ADVISORYEMERGENCY WATER MAIN SHUTDOWNDATE OF NOTIFICATION: April 4th, 2022Due to repairing a water distribution system pipe at 1530 E 8th CT, this notice is a precautionary advisory that ALL water used for drinking, cooking, making ice, brushing teeth, or washing dishes be boiled. A rolling boil of one minute is sufficient. As an alternative, bottled water may be used.The precautionary boil water advisory will remain in effect until the problem has been corrected and a bacteriological survey shows that the water is safe to drink.Should you have any questions, please contact the Public Works, Customer Service Department at 305-556-3800. The area(s) affected by this work are: North: East 16th PlaceSouth: East 14th StreetEast: East 9th CourtWest: East 8th CourtWe apologize for any inconvenience.Sincerely,Department of Public Works City of Hialeah


text:
Bruce Alfred Elder
Rank/Rate/Branch: Sub-Lieutenant
Location: NSW AUSTRALIA
Force: RANR
Service Number: Not Applicable
Date of Enlistment: 3-Sep-1939
Home Port/Port Division: Sydney, NSW
Roll Of Honour: Manly, NSW
Memorial Location: Panel 60, Column 2
Date Of Birth: 3-Sep-1920 (died at age 21)
Place Of Birth: Maitland, NSW
Next Of Kin: Son of Alfred Robert and Eileen Mary Edith Elder, of Manly, New South Wales, Australia
To obtain further records from the National Archives,
please click here
If you have a photograph of this individual CLICK HERE to please read our information on how to make submissions
Terms Explained
The rank(officers), rate (non-commissioned) held by the individual at their date of discharge/death with specialist task, or trade held.
Location the individual was recorded as being from according to their Service Record.
Reference to one of the three branches of Australia's defence forces - Royal Australian Navy (RAN), (RANR) Reserves; Australian Army; Royal Australian Air Force (RAAF); or the Australian Merchant Navy (MN).
Service Number
The number allocated to the individual on enlistment into one of the three branches of Australia's defence forces. This number may be numeric, or an alpha/numeric combination. RAN officers, some RAN ratings and merchant mariners do not have a service number. In these cases, the words 'not applicable' will be displayed in the Service Number field on the Service Record screen.
Birth Date
The date nominated by the individual as their date of birth.
Birth Place
The city/town/country nominated by the individual as their place of birth.
Next Of Kin
The person nominated as being the next of kin by the individual.
Enlistment Date
The date an individual signed their enlistment Attestation Form for service in Australia's defence forces or, for the Merchant Navy, the date a merchant mariner engaged on a ship at the commencement of, or, during the war.
Home Port/Port Division
RAN - Melbourne and Sydney were the Home Ports accepted for Officers of the RAN. Melbourne, Sydney & Fremantle were accepted as Port Divisions for ratings of the RAN.
Roll Of Honour
Indicates the individual's name is listed on a community Roll of Honour in Australia. This information has been sourced from individual casualty records held by the Office of Australian War Graves.
Memorial Location
Name location on the Roll of Honour, Australian War Memorial, Canberra (unless specified).


text:
Fiverr and Upwork are becoming some of the most popular ways to earn money online. Each has a very distinct means of providing services and each also has its fair share of advantages and disadvantages. The best answer is Upwork certainly wins out, however. So what makes them such a great option for making money?
Freelance – The two Fiverr and Upwork provide a market where you can hire a variety of freelance talents for a price. Your chosen freelancer is going to be a part of a team that will select projects for you based on the specific talents they possess. With Fiverr and Upwork, you can pick from various people, which means you will have more options for projects that are both unique and interesting. For Fiverr, if you do not like the project you've been assigned, simply cancel the order and keep looking for another interesting opportunity. For Upwork, simply give the freelancer your contact information so they can contact you if they have any other jobs you may be able to participate in.
Team Selection – The two sites work in conjunction with one another to make certain that you don't just hire a random talent. When you hire a freelancer via Fiverr or Upwork, you have just one shot at hiring themsince you already made your decision about who you want to hire. This stops you from hiring a possibly less than proficient freelancer, which is always a risk on your part because you're putting your faith in their skills.
Reviews Report – One of the greatest aspects of Fiverr and Upwork is the ease by which you can obtain feedback from other freelancers about the person you are considering hiring. Both sites allow you to read reviews from other customers who have used the service before you. You may read these reviews and get a feel for how the freelancer functions, what his/her strengths and weaknesses are, etc.. This information can be extremely valuable when it comes to hiring a person who's ideal for you.
Exclusive Projects – Fiverr and Upwork provide a number of exclusive projects which are only available to contractors or freelancers using their services. If you're hiring freelancers on Fiverr or Upwork, you have access to a huge number of exciting new projects no matter what your experience level is. You'll be able to hire anyone from a beginner with little to no experience, to a master of all things video games.
Upwork Features – Fiverr and Upwork both provide a variety of unique characteristics that can prove useful to both customers and contractors. One such feature is the ability to leave reviews on projects which you're working on. These reviews report directly to you, allowing you to keep track of how well the job is doing. Reviews can also be shared with friends, helping them to learn if the person they are talking with has done outstanding work on their petition. If you employ freelancers with reviews, you will have a much better idea of how reliable they are.
Freelance Reviews – If you are using Fiverr or Upwork, odds are you have come across some freelancers who have given exceptional services. Perhaps they impressed you with their creativity, or perhaps you saw their portfolio and determined that you need to work with them. If you do not know where to look for comments, you can always request a Fiverr or Upwork freelance review. In any event, you will be presented with two reviews, one from the freelancer himself, and one from a client that has worked with the freelancer.
Fiverr Alternatives – One major advantage of using five alternatives is that there are fewer risks involved in hiring freelancers. Since there are lots of men and women who use these sites to market products or services, there's a good chance that there'll be people out there who are trying to rip you off. Since you can't physically check the quality of a service before it's delivered, you want to rely on feedback from other people before making a decision. Since more people use these websites than ever before, you are much more likely to find honest Fiverr professionals than you should find shady ones on these sites.


text:
Newport Beach, CA -- Acacia Research Corporation (Nasdaq:ACTG) announced today that its Data Network Storage LLC subsidiary has entered into a settlement and license agreement with Netgear, Inc. covering a patent portfolio that relates to storage area network technology. This agreement resolves patent litigation that was pending in the United States District Court for the Southern District of California.
About Acacia Research Corporation
Acacia Research's subsidiaries partner with inventors and patent owners, license the patents to corporate users, and share the revenue. Acacia Research's subsidiaries control over 140 patent portfolios, covering technologies used in a wide variety of industries.
Information about Acacia Research is available at www.acaciatechnologies.com and www.acaciaresearch.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.